It Is Time to Consider Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth

It Is Time to Consider Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth

Bibliographic Details
Main Authors:	Megan M. Oberle, Aaron S. Kelly
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-10-01
Series:	Frontiers in Endocrinology
Subjects:	GLP-1 receptor agonists pedatrics type 2 diabetes obesity weight management adolescents
Online Access:	https://www.frontiersin.org/article/10.3389/fendo.2019.00738/full

Similar Items

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
by: Seungah Lee, et al.
Published: (2017-03-01)

An overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning
by: Maryam Rameshrad, et al.
Published: (2020-05-01)

Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity
by: David C. D. Hope, et al.
Published: (2021-09-01)

Controlled Release of Pyrimidine Compound Using Polymeric Coated ZIF-8 Metal-Organic Framework as Glucagon-Like Peptide-1 Receptor Agonist Carrier
by: Shaikha S. AlNeyadi, et al.
Published: (2020-09-01)

Effects of insulin analogs and glucagon-like peptide-1 receptor agonists on proliferation and cellular energy metabolism in papillary thyroid cancer
by: He L, et al.
Published: (2017-11-01)

Amelioration of muscle wasting by glucagon‐like peptide‐1 receptor agonist in muscle atrophy
by: Yeonhee Hong, et al.
Published: (2019-08-01)

Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists
by: Ghadeer K. Dawwas, et al.
Published: (2018-07-01)

Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan
by: Gelhorn HL, et al.
Published: (2016-07-01)

Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
by: Alessandro Mantovani, et al.
Published: (2021-01-01)

Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US
by: Lin J, et al.
Published: (2016-12-01)

One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial
by: Louise Vedtofte, et al.
Published: (2020-10-01)

Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?
by: Hwi Seung Kim, et al.
Published: (2021-09-01)

Glucagon-Like Peptide-1 Receptor Agonist Attenuates Autophagy to Ameliorate Pulmonary Arterial Hypertension through Drp1/NOX- and Atg-5/Atg-7/Beclin-1/LC3β Pathways
by: Yi-Chia Wu, et al.
Published: (2019-07-01)

Role of metformin, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) receptor agonists, and orlistat based multidrug therapy in glycemic control, weight loss, and euglycemia in diabesity: A real-world experience
by: Deep Dutta, et al.
Published: (2019-01-01)

Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis
by: Yoon Ji Kim, et al.
Published: (2020-08-01)

Experiences with Glucagon-Like Peptide-1 Receptor Agonist in Children with Acquired Hypothalamic Obesity
by: Jiska van Schaik, et al.
Published: (2020-08-01)

Glucagon-like peptide-2 reduces the obesity-associated inflammation in the brain
by: Domenico Nuzzo, et al.
Published: (2019-01-01)

Combinatorial Targeting of the Glucagon-Like Peptide-1 And Sulfonylurea-1 Receptors Using a Complimentary Multivalent Glucagon-Like Peptide-1/Glibenclamide Ligand for the Improvement of β-Cell Targeting Agents and Diabetic Treatment
by: Hart, Nathaniel
Published: (2013)

Glucagon-Like Peptide 1 and Taste Perception: From Molecular Mechanisms to Potential Clinical Implications
by: Mojca Jensterle, et al.
Published: (2021-01-01)

The Role of Glucagon-like Peptides in Experimental Type 1 Diabetes
by: Hadjiyianni, Irene Ioanna
Published: (2010)

The Role of Glucagon-like Peptides in Experimental Type 1 Diabetes
by: Hadjiyianni, Irene Ioanna
Published: (2010)

Effects of exercise on glucagon-like peptide-1 (GLP-1)
by: Shin-ya Ueda, et al.
Published: (2013-06-01)

Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review
by: Teshome G, et al.
Published: (2020-09-01)

Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases
by: Maddalena Grieco, et al.
Published: (2019-10-01)

Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model
by: Ling-Yu Zhang, et al.
Published: (2021-01-01)

Patient preferences for glucagon-like peptide-1 receptor–agonist treatment attributes
by: Thieu VT, et al.
Published: (2019-04-01)

Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis
by: Chloe Wong, et al.
Published: (2021-04-01)

Activation of the central nervous system by circulating Glucagon-Like Peptide-1
by: Klustaitis, Kori M.
Published: (2009)

Dual GIP–GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential
by: Bastin M, et al.
Published: (2019-09-01)

Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
by: Maria Mirabelli, et al.
Published: (2021-03-01)

Radiation-induced oxidative injury of the ileum and colon is alleviated by glucagon-like peptide-1 and -2
by: Mustafa Deniz, et al.
Published: (2015-04-01)

First-in-class positron emission tomography tracer for the glucagon receptor
by: Irina Velikyan, et al.
Published: (2019-02-01)

The Role of Central Nervous System Glucagon-Like Peptide-1 in the Regulation of Energy Balance
by: Barrera, Jason G.
Published: (2009)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
by: Xin Zhao, et al.
Published: (2021-08-01)

The Interplay of Glucagon-Like Peptide-1 Receptor Trafficking and Signalling in Pancreatic Beta Cells
by: Amaara Marzook, et al.
Published: (2021-05-01)

L-cell Arntl is required for rhythmic glucagon-like peptide-1 secretion and maintenance of intestinal homeostasis
by: Sarah E. Martchenko, et al.
Published: (2021-12-01)

Polypharmacy in pediatric patients and opportunities for pharmacists' involvement
by: Horace AE, et al.
Published: (2015-08-01)

Ghrelin and Glucagon-Like Peptide-1: A Gut-Brain Axis Battle for Food Reward
by: Lea Decarie-Spain, et al.
Published: (2021-03-01)

A Combination of Glucagon-Like Peptide-1 Receptor Agonist and Dietary Intervention Could Be a Promising Approach for Obesity Treatment
by: Chooi Yeng Lee
Published: (2021-09-01)

GRK Inhibition Potentiates Glucagon-Like Peptide-1 Action
by: Seunghun P. Lee, et al.
Published: (2021-05-01)